Stock RNAC CARTESIAN THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Cartesian Therapeutics, Inc.

Equities

RNAC

US8162123025

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-02 pm EDT 		5-day change 1st Jan Change
24.43 USD +7.91% Intraday chart for Cartesian Therapeutics, Inc. +17.91% +18.12%
Apr. 23 Leerink Partners Starts Cartesian Therapeutics With Outperform Rating, $39 Price Target MT
Mar. 14 Cartesian Therapeutics, Inc Receives Notice from Audentes Therapeutics, Inc of Astellas? Termination of the License and Development Agreement CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
BU
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
BU
Cartesian Therapeutics Announces New Employment Inducement Grants
BU
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
AQ
Cartesian Therapeutics : Termination of Material Agreement - Form 8-K
PU
Cartesian Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
AQ
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
AQ
Cartesian Therapeutics Announces New Employment Inducement Grant
AQ
Cartesian Therapeutics Establishes New Corporate Headquarters and State-of-the-Art mRNA Cell Therapy cGMP Manufacturing Facility in Frederick, Maryland
AQ
Cartesian Therapeutics Announces New Employment Inducement Grants
AQ
Kaskela Law LLC Announces Investigation of Cartesian Therapeutics, Inc. (NASDAQ: RNAC) and Encourages Investors to Contact the Firm
PR
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
AQ
Cartesian Therapeutics Announces Positive Long-Term Follow-Up Data from Phase 2a Study of Lead mRNA Cell Therapy Candidate Descartes-08 in Patients with Myasthenia Gravis
AQ
Selecta Biosciences Announces Merger with Cartesian Therapeutics
AQ
Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
AQ
Half-Yearly Report January-June 2023
AQ
Selecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 Economics
AQ
SELECTA BIOSCIENCES INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Selecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of Rheumatology
AQ
Interim Report January-March 2023
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RNAC Stock
  4. News Cartesian Therapeutics, Inc.
  5. Press Releases